Purdie Jennifer L, Kowle Ronald L, Langland Amie L, Patel Chetan N, Ouyang Anli, Olson Donald J
Bioproduct Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285.
Biotechnol Prog. 2016 Jul 8;32(4):998-1008. doi: 10.1002/btpr.2289. Epub 2016 May 13.
To enable subcutaneous administration of monoclonal antibodies, drug product solutions are often needed at high concentrations. A significant risk associated with high drug product concentrations is an increase in aggregate level over the shelf-life dating period. While much work has been done to understand the impact of drug product formulation on aggregation, there is limited understanding of the link between cell culture process conditions and soluble aggregate growth in drug product. During cell culture process development, soluble aggregates are often measured at harvest using cell-free material purified by Protein A chromatography. In the work reported here, cell culture media components were evaluated with respect to their impact on aggregate levels in high concentration solution drug product during accelerated stability studies. Two components, cysteine and ferric ammonium citrate, were found to impact aggregate growth rates in our current media (version 1) leading to the development of new chemically defined media and concentrated feed formulations. The new version of media and associated concentrated feeds (version 2) were evaluated across four cell lines producing recombinant IgG4 monoclonal antibodies and a bispecific antibody. In all four cell lines, the version 2 media reduced aggregate growth over the course of a 12 week accelerated stability study compared with the version 1 media, although the degree to which aggregate growth decreased was cell line dependent. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:998-1008, 2016.
为实现单克隆抗体的皮下给药,通常需要高浓度的药品溶液。与高浓度药品相关的一个重大风险是在保质期内聚集体水平会增加。虽然已经开展了大量工作来了解药品配方对聚集的影响,但对于细胞培养工艺条件与药品中可溶性聚集体生长之间的联系却了解有限。在细胞培养工艺开发过程中,通常在收获时使用通过蛋白A层析纯化的无细胞材料来测量可溶性聚集体。在本文报道的工作中,在加速稳定性研究期间评估了细胞培养基成分对高浓度溶液药品中聚集体水平的影响。发现半胱氨酸和柠檬酸铁铵这两种成分会影响我们当前培养基(版本1)中的聚集体生长速率,从而促使开发新的化学成分确定的培养基和浓缩补料配方。在生产重组IgG4单克隆抗体和双特异性抗体的四种细胞系中对新版本的培养基及相关浓缩补料(版本2)进行了评估。在所有四种细胞系中,与版本1培养基相比,在为期12周的加速稳定性研究过程中,版本2培养基降低了聚集体的生长,尽管聚集体生长降低的程度因细胞系而异。© 2016美国化学工程师学会生物技术进展,32:998 - 1008,2016年。